About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rheumatoid Arthritis Clinical Trials in New York | 4,168 Studies | Clareo Health

Clinical Trials Rheumatoid ArthritisNew York

Rheumatoid Arthritis Clinical Trials in New York

Find 4,168 clinical trials for rheumatoid arthritis near New York, New York. Connect with research centers in your area.

All Rheumatoid Arthritis trials nationwide All trials in New York

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1481-1500 of 4,168 trials

AVAILABLE< 1 mile

Intermediate Expanded Access Protocol CNMAu8.EAP04

NCT06408727

An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012

ALSAmyotrophic Lateral SclerosisPALS

Clene Nanomedicine

Fort Lauderdale, Florida, United States • Chicago, Illinois, United States • Chicago, Illinois, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121

Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles

Mylan Technologies Inc.1,319 participantsStarted Oct 2021

Mobile, Alabama, United States • Mobile, Alabama, United States • Mesa, Arizona, United States +97 more locations

Rheumatoid Arthritis Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

NCT03220035

This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more

National Cancer Institute (NCI)4 participantsStarted Nov 2017

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +113 more locations

COMPLETEDNA< 1 mile

Aromatherapy in Total Knee Replacement

NCT06045078

The purpose of this pilot randomized controlled trial is to investigate the effects of aromatherapy on postoperative anxiety and pain in total knee replacement patients. The primary research questions are: Does Lavender-Peppermint Aromatherapy reduce post operative anxiety in patients after primary total knee replacement when compared to placebo? Does Lavender-Peppermint Aromatherapy reduce post operative pain in patient after primary total knee replacement when compared to placebo? Participants will be assigned to one of the following groups at random: * Intervention: Aromatherapy with the lavender-peppermint scent * Control: Aromatherapy with the almond oil scent Participants will also be asked to complete pre- and post-operative questionnaires. Researchers will compare both groups (intervention vs control) to see if aromatherapy reduces post-operative anxiety and/or pain.

Total Knee ReplacementPost-operative Nausea and VomitingOpioid Use+3 more

Hospital for Special Surgery, New York30 participantsStarted Oct 2023

New York, New York, United States

COMPLETEDNA< 1 mile

Tele-Rehabilitation Home Exercise Program for Ambulatory Adults With Cerebral Palsy

NCT05098379

This study aims to determine if a tele-rehabilitation home exercise program is feasible to promote adherence to a fitness and mobility exercise program in ambulatory adults with cerebral palsy (GMFCS I, II, III) aged 21- 60 year old, and second, to determine if a tele-health exercise program improves fitness and functional mobility for participants.

Columbia University6 participantsStarted Oct 2021

New York, New York, United States

AVAILABLE< 1 mile

Intermediate-Size Expanded Access Protocol (EAP) for LP352

NCT06149663

This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.

Dravet SyndromeLennox Gastaut SyndromeDevelopmental and Epileptic Encephalopathies

Longboard Pharmaceuticals

Downey, California, United States • Los Angeles, California, United States • San Francisco, California, United States +19 more locations

Approved For Marketing< 1 mile

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

NCT03906331

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Non Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+4 more

Eli Lilly and Company

Goodyear, Arizona, United States • Scottsdale, Arizona, United States • Duarte, California, United States +61 more locations

COMPLETEDNA< 1 mile

International EXPAND Heart Pivotal Trial

NCT02323321

To evaluate the effectiveness of the OCS™ Heart to recruit, preserve and assess donor hearts that may not meet current standard donor heart acceptance criteria (as identified above) for transplantation to potentially improve donor heart utilization for transplantation

Heart Transplant

TransMedics75 participantsStarted Sep 2015

Los Angeles, California, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +8 more locations

COMPLETEDNA< 1 mile

Heart EXPAND Continued Access Protocol

NCT03835754

The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria for transplantation in this continued access protocol.

Heart Transplant

TransMedics75 participantsStarted Apr 2019

Los Angeles, California, United States • Palo Alto, California, United States • New Haven, Connecticut, United States +9 more locations

COMPLETEDNA< 1 mile

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

NCT02844465

The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

Temporal Lobe Epilepsy

MedtronicNeuro167 participantsStarted Dec 2016

Newport Beach, California, United States • Palo Alto, California, United States • San Francisco, California, United States +20 more locations

COMPLETEDNA< 1 mile

FluSAFE: Flu SMS Alerts to Freeze Exposure

NCT03274310

Influenza infection results in an estimated 31 million outpatient visits, 55,000 to 974,200 hospitalizations, and 3,000 to 49,000 deaths. Membership in household in which someone else has influenza is the major risk factor for contracting influenza. The household secondary attack rate (SAR) is as high as 19% based on laboratory-confirmed influenza and 30% based on symptoms. Non-pharmaceutical preventive measures, including education, may play a role in decreasing transmission, but are only effective if started within 36 hours of symptom onset in index cases. Yet, most interventions are delayed because they are not initiated until care is sought. The investigators have demonstrated in one primarily Latino, urban community sample, that text messaging can be used to rapidly identify community members with influenza-like illness (ILI) early in an illness. This early identification would enable implementation of an educational intervention in the optimal time frame to reduce influenza transmission. Providing education within a text message is a proven successful strategy to influence behavior. Text messaging itself is scalable, low-cost, and can be used in low literacy populations. However, using text-message based surveillance to trigger a real-time text-message behavioral educational intervention to decrease household influenza transmission has not been assessed.

InfluenzaAcute Respiratory InfectionInfluenza-like Illness

Columbia University1,918 participantsStarted Oct 2017

New York, New York, United States

COMPLETEDPhase 3< 1 mile

Saypha® VOLUME Lidocaine for Midface Augmentation

NCT05386030

The clinical investigation is a randomized, subject- and evaluator-blinded, active treatment controlled, multicenter, clinical investigation, to demonstrate the non inferiority of saypha® VOLUME Lidocaine to one of the devices approved for the same indication (Juvéderm® Voluma™ XC).

Moderate to Severe Midface Volume Deficit

Croma-Pharma GmbH562 participantsStarted Aug 2022

Scottsdale, Arizona, United States • Encino, California, United States • Fremont, California, United States +13 more locations

WITHDRAWNPhase 212 miles

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

NCT06233903

This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to: * compare the findings against other catacholamine transporters * evaluate the imaging results at different time points and in different organs * assess the quality of images with lower doses * compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors

NeuroblastomaPheochromocytomaParaganglioma

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Started Jan 2025

The Bronx, New York, United States

RECRUITINGNA22 miles

The Lily Device Trial

NCT06786078

The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device. The main questions it aims to answer is: * Do patient preserve their hair using the Lily Device after 4 cycles of chemotherapy, when hair preservation is a Grade ≤1 graded by an independent healthcare professional on the Common Terminology Criteria for Adverse Events (CTCAE)? * What is the subject incidence of Grade 1 or above Adverse Device Events (ADE's)?

Chemotherapy Induced Alopecia

Luminate Medical, Inc.85 participantsStarted Dec 2024

Mullica Hill, New Jersey, United States • Vineland, New Jersey, United States • Binghamton, New York, United States +2 more locations

RECRUITING38 miles

External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy

NCT06788977

This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry. The main question it aims to answer is: Is external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy? There are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.

PregnancyMigraineHeadache+3 more

Cefaly Technology550 participantsStarted Nov 2024

Darien, Connecticut, United States

COMPLETED155 miles

Prospective Research in Infants With Mild Encephalopathy

NCT01747863

A multicenter observational pilot study will be conducted to determine the natural history of infants with early diagnosis (≤ 6 hrs of age) of mild neonatal encephalopathy (NE) who are not qualified for therapeutic hypothermia. The intervention includes: neurologic examination by using modified Sarnat score at ≤ 6 hrs of age, 24 hrs and before discharge home, amplitude-integrated electroencephalography (aEEG) at 6 ± 3 hrs of age, brain MRI at before discharge home to 30 days of age and follow-up at 18-22 months of age. Primary outcome is the percentage of mild NE infants with evidence of brain injury defined by the presence of at least 1 abnormality of brain MRI, aEEG or neurologic examination in the neonatal period. Secondary outcome is the percentage of brain MRI, aEEG and neurological exam abnormalities, seizure, length of hospital stay, need of gavage feeds or gastrostomy at discharge home, death and long-term outcome.

Hypoxic-Ischemic EncephalopathyBrain InjuryNeonatal Seizure

McGill University Health Centre/Research Institute of the McGill University Health Centre63 participantsStarted Dec 2012

Detroit, Michigan, United States • Columbus, Ohio, United States • Providence, Rhode Island, United States +4 more locations

COMPLETEDNA169 miles

Dexterous Partial Hand Prosthesis Outcomes

NCT05038566

Liberating Technologies, Inc. (LTI) has developed a dexterous prosthetic fingertip that will be fit onto an i-Digits™ partial hand prosthesis and allow for an additional fine grasp. The device will interface with research participants' existing prostheses and use the same control strategy that is used for their everyday use. Each participant's prosthesis will be restored to their original configuration by the end of their testing period.

AmputationAmputation; Traumatic, HandLimb; Absence, Congenital, Upper+2 more

Liberating Technologies, Inc.4 participantsStarted Jul 2021

Holliston, Massachusetts, United States • Dublin, Ohio, United States

TERMINATEDPhase 2190 miles

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

NCT04440982

This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.

Breast CancerNeoadjuvant Therapy

Lumicell, Inc.98 participantsStarted Sep 2020

Palo Alto, California, United States • Clearwater, Florida, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDPhase 1/2195 miles

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational age) and full-term (born at \>35 weeks gestational age) infants. Participants will be randomized into 1 of 4 dose escalation panels (Panels A to D); an additional panel (Panel E) of full-term infants will receive the same dose as Panel D. Key safety and tolerability variables will be reviewed after each dose panel prior to administering the next-highest dose.

Respiratory Tract InfectionRespiratory Syncytial Virus

Merck Sharp & Dohme LLC183 participantsStarted Sep 2018

Aurora, Colorado, United States • Homestead, Florida, United States • Miami, Florida, United States +31 more locations

COMPLETEDPhase 4712 miles

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193

The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy. Each participant was enrolled in Cycle 1 (on which the primary study objectives were based), consisting of the 3-day treatment cycle and 14 days of follow-up for a total of 17 days.

Chemotherapy-induced Nausea and Vomiting

Merck Sharp & Dohme LLC103 participantsStarted Sep 2019

Phoenix, Arizona, United States • Los Angeles, California, United States • Chicago, Illinois, United States +23 more locations

PreviousPage 75 of 209Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia